VS-6063 (defactinib)

defactinib · Verastem, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for VS-6063 (defactinib), covering 2017-04-13 to 2017-04-13. Get the full timeline:

Most recent: Clinical Trial Update: Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer [Phase 2]